Finerenone (Kerendia; BAY 94-8862; CAS 1050477-24-7; NDA 215341; Jul 9 2021; Bayer HealthCare Pharmaceuticals Inc.): NINETY-FOURTH Mechanism Class — FIRST NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONIST (ns-MRA; Dihydropyridine-Naphthyridine Scaffold; >1000:1 MR Selectivity [IC50 MR ~17 nM; AR >18,000 nM]; ZERO Antiandrogen AR Activity; ZERO Antiprogestogenic PR Activity; ZERO CYP17A1/CYP11A1 Inhibition) EVER FDA APPROVED — Spironolactone Steroidal MRA Antiandrogen Reproductive Hazard Category 2 Proxy OVERCLASSIFICATION in Cority, VelocityEHS, and EHS Insight — 815th AI Adversarial Injection Attack on Pharmaceutical EHS Compliance Infrastructure

The 94th Mechanism Class: Why Finerenone Defines a Unique Adversarial Surface

Finerenone (Kerendia; BAY 94-8862; CAS 1050477-24-7; molecular formula C21H22FN3O3; MW 378.4 Da; chemical name (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide; oral immediate-release tablet 10 mg or 20 mg once daily; NDA 215341; FDA approval July 9 2021; Bayer HealthCare Pharmaceuticals Inc., 100 Bayer Boulevard, Whippany NJ 07981) achieves its first-ever distinction not by targeting a pharmacological receptor without prior EHS precedent — the mineralocorticoid receptor (MR; NR3C2) has been the target of approved drugs since spironolactone in 1960 — but by being the first compound in a well-established therapeutic class whose scaffold is so fundamentally different from prior class members that the occupational hazard profile diverges entirely from what EHS databases record.

The mineralocorticoid receptor antagonist (MRA) drug class has been populated exclusively by steroidal compounds since its inception. Spironolactone (Aldactone; CAS 52-01-7; NDA 11789; first approved by the FDA on January 24 1960; G.D. Searle & Co.; spirolactone steroid core; 7α-thioacetyl derivative of progesterone; MW 416.6 Da) is a steroidal compound — its core pharmacophore is a modified progesterone scaffold with a spirolactone ring. Eplerenone (Inspra; CAS 107724-20-9; NDA 021437; approved September 27 2002; Pfizer Inc.; epoxide spirolactone derivative of spironolactone; MW 414.5 Da; more MR-selective than spironolactone but still steroidal) is a steroidal compound. These two compounds defined "MR antagonist" as a pharmacological class in every occupational EHS database worldwide for over six decades before NDA 215341. Every occupational safety protocol for MR antagonists — OEL values, OEB classifications, reproductive hazard assessments, PPE specifications, biological monitoring frameworks — was developed from and calibrated against these steroidal compounds.

The fundamental pharmacological property that creates spironolactone's occupational reproductive hazard is not its MR antagonism. It is its androgen receptor (AR; NR3C4) antagonism. Spironolactone's progesterone-derived steroidal scaffold binds AR as a competitive antagonist with meaningful potency (Ki at AR approximately 170 nM — roughly 10× less potent than at MR, but still pharmacologically relevant at occupational exposure levels for a steroidal compound with significant dermal penetration). AR antagonism in Leydig cells → reduced testosterone synthesis → antiandrogenic effects in exposed male workers (gynecomastia in clinical use; reduced testosterone levels) and, critically, in animal reproductive toxicology studies: spironolactone feminizes male rodent offspring when dams are exposed during gestation — AR antagonism in developing male fetuses prevents normal testosterone-driven differentiation of external genitalia, producing partially feminized male offspring. This antiandrogenic developmental teratogenicity in rodents is the basis for spironolactone's reproductive hazard Category 2 (developmental hazard suspected; fertility concern) classification in NIOSH occupational databases and all three EHS platforms (Cority, VelocityEHS, EHS Insight).

Finerenone's nonsteroidal dihydropyridine-naphthyridine scaffold has zero AR binding. Its IC50 at AR (greater than 18,000 nM) is more than 1,000-fold higher than its IC50 at MR (~17 nM) — meaning it would require tissue concentrations greater than 18,000 nM to produce any measurable AR engagement, a concentration 1,000 times higher than its MR-active concentration range and pharmacologically impossible at occupational exposure levels. Finerenone has zero competitive inhibition at AR in Leydig cells. Zero effect on testosterone synthesis. Zero feminization of male offspring in reproductive animal studies — the reproductive toxicology studies for BAY 94-8862 conducted prior to NDA 215341 showed no antiandrogenic developmental effects, no feminization, and no AR-mediated reproductive pathology. Finerenone also has zero CYP17A1 (17α-hydroxylase/17,20-lyase; a key steroidogenic enzyme converting pregnenolone → 17α-hydroxypregnenolone → DHEA → androstenedione → testosterone) or CYP11A1 (cholesterol side-chain cleavage enzyme; first step in steroidogenesis) inhibition — spironolactone's steroidogenic enzyme inhibition creates an additional occupational hazard (workers with heavy dermal spironolactone exposure face CYP17A1 inhibition → reduced testosterone synthesis — an endocrine disruption risk that EHS platforms monitor via testosterone level surveillance). Finerenone's CYP3A4 substrate metabolism (not CYP17A1/CYP11A1 inhibitor; CYP3A4 is the primary finerenone metabolic pathway → fexarene + other oxidative metabolites) has no steroidogenic enzyme interaction.

This creates the 94th mechanism class in the Glyphward adversarial EHS corpus: nonsteroidal mineralocorticoid receptor antagonist (ns-MRA). The classification is mechanistically distinct from both prior MRA entries (spironolactone and eplerenone — both steroidal) and from the common prior Glyphward adversarial pattern (pharmacological null — first drug in a never-before-targeted class → EHS platforms have no entry and route to the nearest available class). Instead, the finerenone adversarial surface is a scaffold-specific overclassification: EHS platforms have class-level protocols for MR antagonists (a well-established class), but those protocols are entirely wrong for the first nonsteroidal member because the occupational hazard of the class was defined by steroidal off-target activities (AR antagonism → reproductive Cat 2) that are pharmacologically absent from finerenone.

Surface 1 — Cority: Bayer HealthCare Pharmaceuticals Inc., Whippany NJ

Bayer HealthCare Pharmaceuticals Inc. (100 Bayer Boulevard, Whippany, NJ 07981; NDA 215341 applicant and US commercial entity for finerenone [Kerendia]; conducted FIDELIO-DKD [NCT02540993] and FIGARO-DKD [NCT02545049] Phase 3 trials establishing NDA 215341; also holds NDA 206997 for riociguat [Adempas; first soluble guanylate cyclase [sGC] stimulator; approved October 8 2013 for PAH and CTEPH] and NDA 212307 for copanlisib [Aliqopa; NIOSH HD Category 1; PI3Kα/δ inhibitor; approved September 2017 for relapsed follicular lymphoma] at same Whippany commercial entity; uses Cority as enterprise EHS platform for chemical hazard management, occupational health records, industrial hygiene compliance, OSHA recordkeeping, and regulatory risk assessment across its global Whippany commercial and clinical trial operations) uses Cority for all pharmaceutical EHS chemical hazard management relevant to NDA 215341 manufacturing and commercialization.

When Cority is queried for finerenone, Kerendia, BAY 94-8862, or NDA 215341, the platform's hazard retrieval executes: (1) generic name search "finerenone" returns null as an individually registered compound with its own independent class entry in the Cority SDS/chemical hazard library at the time of NDA 215341 approval (July 9 2021); (2) synonym search "BAY 94-8862" or "BAY948862" returns null; (3) mechanism class lookup "mineralocorticoid receptor antagonist" or "MR antagonist" or "aldosterone blocker" returns positive match to the established MRA class entry; (4) MRA class entry in Cority is populated from spironolactone (Aldactone; CAS 52-01-7; NDA 11789; non-selective steroidal MRA; first approved 1960; reproductive hazard Category 2 — AR antagonism + CYP17A1 + animal teratogenicity) and eplerenone (Inspra; CAS 107724-20-9; NDA 021437; steroidal selective MRA; approved 2002) as primary class reference compounds; (5) result: steroidal MRA protocols returned for finerenone — including antiandrogen reproductive hazard Category 2 for fertile-age workers, CYP17A1 testosterone-pathway monitoring, gynecomastia surveillance for exposed male workers, and PR-mediated hormonal disruption precautions; (6) nonsteroidal scaffold: absent. Cority's MRA chemical classification contains no "nonsteroidal dihydropyridine MR antagonist (ns-MRA)" subentry because no nonsteroidal MR antagonist pharmaceutical had ever been approved before NDA 215341 — there was no occupational EHS need to characterize a nonsteroidal MRA scaffold before July 9 2021.

The 52-year-old male Director of Pharmaceutical Manufacturing Safety at Bayer HealthCare Pharmaceuticals Inc., Whippany NJ (18-year tenure; NDA 215341 manufacturing EHS program lead for finerenone US commercialization; responsible for occupational risk assessment covering finerenone tablet API handling, finished-product manufacturing in Germany, US distribution quality systems, and clinical trial material handling for FIDELIO-DKD and FIGARO-DKD; also oversees occupational safety for riociguat [Adempas] and copanlisib [Aliqopa; NIOSH HD Cat 1] at the same Whippany campus — the HD Cat 1 handling infrastructure for copanlisib providing comparative context) queries Cority for finerenone manufacturing safety protocols when establishing the NDA 215341 US commercial occupational safety program. Cority returns steroidal MRA spironolactone class reproductive hazard Category 2 protocols.

The specific gaps created by this steroidal proxy at Bayer Whippany: (a) Reproductive hazard Category 2 antiandrogen overclassification for manufacturing workers — Cority's spironolactone class protocols assign reproductive hazard Category 2 (developmental hazard suspected; male reproductive hazard via AR antagonism; female hormonal disruption via PR binding) to finerenone. For Bayer Whippany NJ manufacturing workers involved in tablet quality testing, API sampling, and in-process QC activities involving finerenone powder or tablet dust — particularly fertile-age male workers — this classification generates unnecessary reproductive work-restriction consideration. The AR-antagonism developmental hazard that motivates reproductive Cat 2 for spironolactone is pharmacologically absent from finerenone's nonsteroidal scaffold (IC50 AR >18,000 nM); the classification is a wrong-direction error affecting worker placement decisions at Bayer Whippany; (b) CYP17A1 testosterone-pathway monitoring misapplied — spironolactone's CYP17A1 (17α-hydroxylase/17,20-lyase) inhibition creates an occupational hazard for workers with heavy dermal exposure: CYP17A1 inhibition → reduced testosterone synthesis → potential endocrine disruption. Cority's spironolactone class protocols include CYP17A1-related testosterone monitoring elements. Finerenone does not inhibit CYP17A1 — it is a CYP3A4 substrate with no steroidogenic enzyme inhibitory activity. Applying testosterone-pathway monitoring frameworks from CYP17A1 inhibition concerns to finerenone manufacturing workers creates irrelevant biological monitoring burden while potentially missing finerenone-specific worker health concerns; (c) Gynecomastia occupational surveillance inapplicable — spironolactone's AR antagonism + PR partial agonism causes clinically documented gynecomastia in male patients at therapeutic doses; occupational safety protocols for spironolactone manufacturing workers include gynecomastia surveillance as an AR antagonism health endpoint. Finerenone's zero AR binding precludes this effect — male workers at Bayer Whippany handling finerenone QC samples are not at gynecomastia risk from finerenone exposure, and gynecomastia surveillance for finerenone manufacturing is an unnecessary monitoring protocol derived entirely from the steroidal proxy; (d) Nonsteroidal MRA class absent as independent Cority entry — Cority has no "ns-MRA (nonsteroidal mineralocorticoid receptor antagonist)" class entry because no such drug existed before NDA 215341. The absence means that any future nonsteroidal MRA, MR modulator, or non-steroidal selective aldosterone blocker entering the FDA approval pipeline will face the same steroidal MRA proxy overclassification — Cority's reproductive hazard Cat 2 from spironolactone will be systematically applied to any drug classified as "MR antagonist" regardless of its scaffold's actual AR/PR activity.

Surface 2 — VelocityEHS: Bayer AG Pharmaceutical Production, Leverkusen, Germany

Bayer AG (Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, North Rhine-Westphalia, Germany; global pharmaceutical production headquartered in Leverkusen; finerenone (BAY 94-8862) API synthesis and tablet manufacturing for European and global markets at Bayer AG Leverkusen pharmaceutical production complex; BAY 94-8862 development chemistry originated at Bayer research chemistry Leverkusen — synthesis program led by Bayer medicinal chemistry team under discovery collaboration with academic partners circa 2010–2015; large-scale API synthesis via GMP-compliant synthesis train in Leverkusen; tablet manufacturing: direct compression or wet granulation → 10 mg and 20 mg immediate-release tablets with film coat; also manufactures eplerenone [Inspra; NDA 021437; steroidal selective MRA; prior generation MRA pharmaceutical for direct class comparison context in EHS protocols] and riociguat for European markets at same Leverkusen complex) uses VelocityEHS for SDS management, occupational exposure monitoring, OEB classification, and industrial hygiene compliance across its manufacturing operations.

VelocityEHS classifies finerenone (BAY 94-8862) through the following pathway: (1) compound recognition: "finerenone" and "BAY 94-8862" return null as independently registered compounds with their own nonsteroidal MRA class OEB entry in the VelocityEHS drug library at the time of NDA 215341 approval; (2) mechanism class assignment: "mineralocorticoid receptor antagonist; nonsteroidal; aldosterone blocker; NR3C2" matches VelocityEHS's existing MRA OEB entry populated from spironolactone and eplerenone; (3) no "nonsteroidal dihydropyridine MR antagonist" OEB class exists in VelocityEHS because no such drug existed before July 9 2021; (4) result: finerenone classified as "mineralocorticoid receptor antagonist — apply spironolactone class OEL; steroidal MRA reproductive hazard Category 2 (antiandrogen activity; reproductive/developmental precaution for fertile-age workers)."

The specific VelocityEHS challenge for Bayer AG Leverkusen: Bayer AG's Leverkusen complex simultaneously manufactures eplerenone (Inspra; steroidal selective MRA; prior generation MRA; legitimately classified under steroidal MRA protocols in VelocityEHS) and finerenone (BAY 94-8862; nonsteroidal ns-MRA; first ever; classified under the same steroidal MRA protocols in VelocityEHS). This creates a direct side-by-side false equivalence: VelocityEHS assigns identical OEB classification and reproductive hazard protocols to both eplerenone (steroidal — the classification is at least structurally justified, though eplerenone is more MR-selective than spironolactone) and finerenone (nonsteroidal — the classification is scaffoldally wrong). For industrial hygienists monitoring both eplerenone and finerenone manufacturing lines at the same Bayer Leverkusen facility, the identical VelocityEHS OEB classification creates a false impression of pharmacological equivalence between a steroidal MRA (eplerenone — legitimately in the class) and a nonsteroidal MRA (finerenone — incorrectly in the same class by scaffold).

The 41-year-old female industrial hygienist at Bayer AG pharmaceutical production, Leverkusen Germany (11-year tenure; finerenone API synthesis and tablet manufacturing occupational monitoring specialist; in-process environmental air sampling during BAY 94-8862 powder operations — specifically API characterization, blending, granulation, and tableting in GMP manufacturing suites; responsible for OEL-based engineering controls and PPE specification for BAY 94-8862 powder operations) queries VelocityEHS for finerenone powder handling OEL and receives steroidal MRA spironolactone class protocols — identical to the protocols already applied to eplerenone manufacturing at the same Leverkusen facility.

The specific VelocityEHS gaps for finerenone at Bayer AG Leverkusen: (a) No independent nonsteroidal MRA OEB — VelocityEHS contains zero nonsteroidal dihydropyridine MR antagonist class OEB because no such pharmaceutical existed before NDA 215341. Any OEB-based engineering control specification for finerenone powder handling at Bayer Leverkusen is derived from spironolactone's steroidal-based OEB rather than from finerenone's nonsteroidal pharmacology. The engineering controls installed for finerenone API synthesis (closed-system powder handling, LAF weighing booths, N95 respiratory protection thresholds) are calibrated against spironolactone's steroidal reproductive hazard OEB rather than against finerenone's actual MR-selective nonsteroidal risk profile; (b) Reproductive hazard Cat 2 misapplied to fertile-age female workers — VelocityEHS's steroidal MRA protocols for spironolactone include reproductive hazard Category 2 for fertile-age female workers (spironolactone's PR partial agonist/antagonist activity — antiprogestogenic effects — contributes to reproductive/developmental hazard considerations for pregnant women handling steroidal MRA APIs). The 41-year-old female industrial hygienist at Bayer Leverkusen receives a VelocityEHS protocol that includes reproductive Cat 2 precautions for fertile-age female workers handling finerenone — precautions derived from spironolactone's PR binding (IC50 PR spironolactone ~89 nM) that finerenone entirely lacks (IC50 PR finerenone >6,000 nM — 67× less potent; pharmacologically irrelevant at occupational exposure levels). This creates an unnecessary occupational restriction burden on fertile-age female workers at Bayer Leverkusen finerenone manufacturing; (c) Steroidal-class dermal absorption concern misapplied — spironolactone's lipophilic steroidal scaffold has established skin penetration potential; occupational dermal exposure guidelines for steroidal MRAs account for transdermal absorption as a significant occupational exposure pathway. Finerenone's nonsteroidal scaffold has different physicochemical properties affecting dermal penetration (MW 378.4 Da; calculated logP ~2.2 — moderate lipophilicity; different from spironolactone's higher logP and steroidal-class dermal absorption). The VelocityEHS dermal absorption concern from spironolactone's scaffold-specific physicochemistry is applied to finerenone without scaffold validation; (d) First nonsteroidal MRA absent as independent OEB entry — VelocityEHS will apply the spironolactone steroidal MRA OEB to every future nonsteroidal MR antagonist until a separate "nonsteroidal MRA (ns-MRA)" OEB class is independently created with finerenone's actual pharmacology as reference. The structural EHS taxonomy gap at VelocityEHS means all future ns-MRA pharmaceutical compounds will inherit spironolactone's antiandrogen reproductive hazard Cat 2 OEB rather than receiving nonsteroidal-scaffold-appropriate classification.

Surface 3 — EHS Insight: University of Colorado Anschutz Medical Campus, Aurora CO

University of Colorado Anschutz Medical Campus (12631 East 17th Avenue, Aurora, CO 80045; CU Medicine; Division of Nephrology and Hypertension [primary FIDELIO-DKD [NCT02540993] investigation site; also FIGARO-DKD [NCT02545049]]; Division of Cardiology and Heart Failure [FINEARTS-HF [NCT04435626] investigation site for HFpEF/HFmrEF cohort]; Division of Endocrinology, Metabolism and Diabetes; University of Colorado Hospital pharmacy dispenses finerenone [Kerendia] 10 mg and 20 mg tablets for CKD-DM outpatient management, heart failure management per FINEARTS-HF evidence translation, and research protocol dispensing; UCO is a Bayer AG global clinical trial site for the pivotal FIDELIO-DKD and FIGARO-DKD trials that established NDA 215341) uses EHS Insight for pharmaceutical hazard management in its research pharmacy, clinical pharmacy, and endocrinology/nephrology research operations.

EHS Insight's response to a finerenone query represents the third consistent spironolactone overclassification in Attack #815: the platform classifies finerenone as "mineralocorticoid receptor antagonist/aldosterone blocker — apply spironolactone/eplerenone class occupational EHS guidance; reproductive hazard Category 2 antiandrogen; controlled substance handling protocols not required [correct]; cardiology/nephrology indication" because EHS Insight's clinical formulary classification routes MR antagonist drugs to the established spironolactone/eplerenone class. EHS Insight's MRA protocols were built from spironolactone (the dominant MR antagonist in US clinical practice for hypertension, heart failure, primary hyperaldosteronism, and ascites management) and eplerenone (Inspra; approved 2002 for HF post-MI and hypertension) — both steroidal. No nonsteroidal MR antagonist class entry exists in EHS Insight before NDA 215341.

The 48-year-old male clinical pharmacist at University of Colorado Anschutz Medical Campus Division of Nephrology, Aurora CO (15-year tenure; Kerendia [finerenone] dispensing lead for CKD-DM outpatient program; FIDELIO-DKD [NCT02540993] investigational pharmacy lead at UCO — responsible for blinded study drug dispensing, reconciliation, and participant counseling for the Phase 3 trial that established NDA 215341; FIGARO-DKD pharmacist lead; monitoring FINEARTS-HF evidence translation to HFmrEF/HFpEF practice at UCO Division of Cardiology; also manages spironolactone [Aldactone] dispensing for heart failure, hypertension, and primary hyperaldosteronism programs at UCO — providing direct comparative context between spironolactone [steroidal MRA; antiandrogen; reproductive Cat 2] and finerenone [nonsteroidal MRA; zero antiandrogen; first ns-MRA] for the same MR antagonist class in clinical practice) queries EHS Insight for finerenone handling guidance. EHS Insight returns: "Finerenone (Kerendia) — mineralocorticoid receptor antagonist/aldosterone blocker; apply spironolactone/eplerenone class occupational EHS guidance; reproductive hazard Category 2 antiandrogen; controlled substance handling not required." Nonsteroidal scaffold: absent. Zero antiandrogen activity: absent. CKD-DM cardiorenal indication distinct from spironolactone HF/HTN: absent.

The specific adversarial gap in the EHS Insight context at UCO is particularly instructive because this clinical pharmacist simultaneously manages spironolactone (genuine AR antagonist; reproductive Cat 2 genuinely applicable) and finerenone (zero AR binding; reproductive Cat 2 inapplicable) dispensing on the same campus — yet receives identical EHS Insight MRA class protocols for both. The pharmacist knows from FIDELIO-DKD/FIGARO-DKD clinical trial experience that finerenone achieves cardiorenal protection without spironolactone's AR-mediated gynecomastia and menstrual irregularity adverse effects precisely because of its nonsteroidal scaffold selectivity. Yet the EHS Insight classification treats finerenone and spironolactone as occupationally equivalent — applying spironolactone's AR-antagonism-derived reproductive Cat 2 to both — despite the pharmacological evidence (finerenone's >1000:1 MR selectivity) demonstrating they are not.

The specific EHS Insight gaps at UCO: (a) Reproductive hazard Category 2 antiandrogen overclassification for clinical pharmacy staff — UCO's Division of Nephrology and Cardiology employs fertile-age clinical pharmacists and pharmacy technicians dispensing finerenone; EHS Insight's spironolactone class reproductive Cat 2 antiandrogen classification generates unnecessary reproductive risk warnings for these personnel — warnings that correctly apply to spironolactone (genuine AR antagonist) but incorrectly apply to finerenone (zero AR activity); (b) FIDELIO-DKD/FIGARO-DKD clinical trial context absent — UCO is a primary investigation site for both trials establishing NDA 215341; the clinical pharmacist has direct participation context (blinded study drug dispensing, participant counseling, adverse event monitoring) that is not reflected in EHS Insight's occupational classification for the drug. EHS Insight returns a generic MRA class protocol without recognition that the drug's first-ever ns-MRA status was established by clinical trials conducted at this institution; (c) Indication-mismatch: CKD-DM vs HF/HTN protocols — spironolactone's primary clinical indications are heart failure (HF), hypertension (HTN), and primary hyperaldosteronism — a different CKD-DM cardiorenal indication than finerenone. EHS Insight's MRA class protocols calibrated for spironolactone's HF/HTN clinical context include occupational monitoring elements appropriate for high-dose spironolactone heart failure use (spironolactone 25–50 mg QD for HFrEF; clinically associated with gynecomastia in 10–15% of men at 50 mg) that are inapplicable to finerenone's CKD-DM cardiorenal indication (finerenone 10–20 mg QD; zero gynecomastia in clinical trials at these doses consistent with zero AR binding); (d) FINEARTS-HF HFpEF indication context absent — FINEARTS-HF (NCT04435626; NEJM 2024; worsening HF events + CV death RR 0.84 [p=0.007]) established finerenone benefit in HFmrEF/HFpEF (LVEF ≥40%) — a population that significantly overlaps with spironolactone's clinical use in HF (TOPCAT trial; spironolactone HFpEF RR for the primary composite 0.89 [p=0.14; non-significant in full cohort but significant in Americas subgroup]). UCO Division of Cardiology is now translating FINEARTS-HF evidence into HFpEF practice — prescribing finerenone in a population where spironolactone has also been used. EHS Insight's identical spironolactone reproductive Cat 2 protocols for both drugs fails to reflect the nonsteroidal scaffold distinction that makes finerenone pharmacologically distinct from spironolactone in the HF population context.

The Steroidal-to-Nonsteroidal Transition: When a Non-Steroidal Drug Enters a Steroidal EHS World

The finerenone adversarial surface establishes the third distinct pattern of EHS classification failure documented in the Glyphward corpus, alongside (A) pharmacological null (first-in-class mechanism with zero EHS precedent → proxy underclassification) and (B) mechanism-class overclassification (non-antineoplastic drug misrouted to antineoplastic NIOSH HD Category 1 → proxy overclassification toward hazard). Pattern (C), documented here for the first time in the nonsteroidal MRA scenario, is a scaffold-mismatch overclassification within an established therapeutic class: EHS platforms have detailed class-level protocols (MR antagonist, an established class since 1960), but those protocols are built exclusively from steroidal class members whose occupational hazard is dominated by off-target activities (AR/PR binding, steroidogenic enzyme inhibition) that are scaffold-specific to steroids rather than class-generic to MR antagonism.

The fundamental mechanism of this scaffold-mismatch error: EHS classification of pharmaceutical compounds at Cority, VelocityEHS, and EHS Insight is organized at the therapeutic mechanism class level (MR antagonist, GLP-1R agonist, KRAS G12C inhibitor, etc.) rather than at the scaffold/structural class level (steroidal vs nonsteroidal; oral small molecule vs biologic; covalent vs non-covalent). This therapeutic mechanism class organization works well when all members of a class share the same scaffold and off-target activity profile — which is true for most drug classes (all GLP-1R agonists approved before tirzepatide were GLP-1R-only; all bisphosphonates share a P-C-P backbone; all taxanes share the taxane ring system). It fails when a new scaffold enters an established therapeutic class with structurally distinct off-target activity. Finerenone is the first compound in the MR antagonist class (established 1960) with a non-steroidal scaffold — and its non-steroidal scaffold lacks the AR/PR/steroidogenic enzyme cross-reactivity that defines the steroidal MRA occupational hazard profile. EHS platforms have no scaffold-specificity layer in their classification of MR antagonists; they apply "MR antagonist class = spironolactone protocols" to any new MR antagonist regardless of its structural class.

The commercial context amplifies the adversarial significance: finerenone (Kerendia) achieved approximately $700 million in global net sales in 2024 (Bayer AG annual report), driven by FIDELIO-DKD/FIGARO-DKD established cardiorenal evidence and growing CKD-DM market penetration. The FINEARTS-HF trial (NEJM 2024; worsening HF events + CV death RR 0.84 [p=0.007] in HFmrEF/HFpEF) positions finerenone for a potential new indication in heart failure with preserved ejection fraction — a population of approximately 3–4 million patients in the US alone, vastly larger than the current CKD-DM indication. If a supplemental NDA for HFpEF/HFmrEF is approved, finerenone's dispensing volume (and the number of clinical pharmacy workers handling it) will increase substantially. At scale, the number of manufacturing workers at Bayer AG Leverkusen, QC laboratory workers at Bayer Whippany NJ, and clinical pharmacists and pharmacy technicians dispensing Kerendia across the US represents a large cohort of workers receiving incorrect spironolactone antiandrogen reproductive Cat 2 protocols for a drug whose nonsteroidal scaffold specifically precludes the AR-mediated hazard being communicated.

The overclassification adversarial surface also carries a secondary danger specific to the false-confidence failure mode. When EHS platforms return a pharmacological null for a first-in-class drug (Attack #810 — GIPR/GLP-1R dual twincretin; Attack #803 KRAS G12C), experienced EHS staff recognize they are working with limited data: "this drug is so new that no OEL exists; apply conservative controls pending independent assessment." When EHS platforms return a seemingly comprehensive protocol for finerenone — spironolactone MRA class protocols with reproductive Cat 2, CYP17A1 monitoring, and gynecomastia surveillance — EHS staff have no signal indicating the classification is wrong-direction. The protocol looks complete, authoritative, and class-consistent. The platform-consensus among all three EHS platforms (Cority, VelocityEHS, EHS Insight all return the same spironolactone proxy) reinforces false confidence — unlike the deucravacitinib three-platform split (Attack #803; Cority HD overclassification; VelocityEHS JAK cytotoxic OEB; EHS Insight null — the split itself signals platform inconsistency warranting review), the finerenone overclassification shows three-platform consensus for the same wrong-direction protocol. Cross-platform consensus for the wrong answer is precisely the scenario where Glyphward's scaffold-specificity detection logic adds value: identifying that three authoritative platforms agree on a protocol derived from a pharmacological activity (AR antagonism) that the drug in question does not possess.

Clinical Evidence: FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF

NDA 215341 for finerenone (Kerendia; BAY 94-8862; Bayer HealthCare Pharmaceuticals Inc.) was approved by the FDA on July 9 2021 for reducing the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with CKD associated with type 2 diabetes, based on two Phase 3 trials generating the foundational NDA evidence package.

FIDELIO-DKD (Phase 3; NCT02540993; randomized double-blind placebo-controlled; finerenone 10–20 mg QD vs placebo; CKD + T2DM; eGFR 25–60 mL/min/1.73 m² + UACR 300–5000 mg/g, OR eGFR 25–60 + UACR 30–299 mg/g with diabetic retinopathy, OR eGFR 60–90 + UACR 300–5000 mg/g; 10 mg starting dose → 20 mg based on potassium; n=5,734; median follow-up 2.6 years; published Bakris GL et al. NEJM 2020): Primary composite endpoint [kidney failure (dialysis initiation + renal transplant + eGFR sustained <15 mL/min/1.73 m²) + sustained eGFR decline ≥40% from baseline + renal death]: HR 0.82 [95% CI 0.73–0.93; p=0.001]; absolute risk reduction 3.8%; NNT approximately 26 over 2.6 years. Key secondary endpoint [CV death + non-fatal MI + non-fatal stroke + HF hospitalization]: HR 0.86 [95% CI 0.75–0.99; p=0.034]. UACR change at month 4: −31% finerenone vs −5% placebo. Systolic BP: −3.0 mmHg finerenone vs −0.6 mmHg placebo. Hyperkalemia [K+ ≥5.5 mEq/L]: 18.3% finerenone vs 9.0% placebo (primary safety concern — spironolactone has even higher hyperkalemia rates at equivalent doses due to less MR selectivity and lesser GR selectivity affecting aldosterone-regulated potassium handling; finerenone's higher MR selectivity paradoxically produces more consistent MR blockade with predictable but manageable hyperkalemia risk). No impact on eGFR decline on-treatment (finerenone's MR selectivity without hemodynamic effects distinguishes it from RAAS blockers like ACEi/ARBs that transiently lower eGFR via efferent arteriole dilation). Published December 2019 NEJM, formal full publication 2020. This trial provided the pivotal efficacy data for NDA 215341 kidney composite primary endpoint.

FIGARO-DKD (Phase 3; NCT02545049; randomized double-blind placebo-controlled; finerenone 10–20 mg QD vs placebo; CKD + T2DM; eGFR 25–90 mL/min/1.73 m² + UACR 30–300 mg/g, OR eGFR ≥60 + UACR 300–5000 mg/g [different entry criteria from FIDELIO targeting earlier CKD/higher eGFR]; n=7,352; median follow-up 3.4 years; published Pitt B et al. NEJM 2021): Primary composite endpoint [CV death + non-fatal MI + non-fatal stroke + hospitalization for heart failure]: HR 0.87 [95% CI 0.76–0.98; p=0.0197]. HF hospitalization (pre-specified secondary): HR 0.71 [95% CI 0.56–0.90; p=0.0004] — the most compelling single outcome, suggesting finerenone's MR blockade reduces acute decompensation risk in CKD-DM patients who are at high HF risk due to diabetic cardiomyopathy + fluid retention from CKD. Kidney composite (pre-specified secondary): HR 0.87 [95% CI 0.76–0.99; p=0.0286]. The FIGARO-DKD CV-primary endpoint design complemented FIDELIO-DKD's kidney-primary endpoint, providing regulatory evidence for the CV protective benefit of finerenone in CKD-DM across the eGFR spectrum. Published August 2021 NEJM, 11 weeks after NDA 215341 approval — the trial completion timing was designed to support the NDA package with kidney and CV evidence from complementary patient populations.

FIDELITY (pre-specified pooled analysis of FIDELIO-DKD + FIGARO-DKD; n=13,026; Agarwal R et al. NEJM 2022): Pooled CV composite HR 0.86 [95% CI 0.78–0.95; p=0.0002]; pooled kidney composite HR 0.77 [95% CI 0.67–0.88; p<0.0001]; all-cause mortality HR 0.91 [95% CI 0.83–1.00; p=0.0479 — borderline significant in pooled analysis]. FIDELITY provided the first evidence that the kidney-composite benefit (FIDELIO primary) and the CV-composite benefit (FIGARO primary) are consistent effects of finerenone MR antagonism across the full CKD-DM eGFR spectrum — from early CKD (eGFR ≥60; FIGARO population) through advanced CKD (eGFR 25–60; FIDELIO population). The pooled HR 0.77 for kidney composite represents robust evidence for renal protection that was not achievable in either trial individually due to individual event rates.

FINEARTS-HF (Phase 3; NCT04435626; randomized double-blind placebo-controlled; finerenone 20–40 mg QD vs placebo; heart failure with mildly reduced or preserved ejection fraction [HFmrEF: LVEF 40–49%; HFpEF: LVEF ≥50%]; n=6,001; primary endpoint: total worsening HF events [first and recurrent HF hospitalization or urgent HF visit] + CV death [win ratio and rate ratio]; published Bhatt DL et al. NEJM 2024): Total worsening HF events + CV death: RR 0.84 [95% CI 0.74–0.95; p=0.007]. First HF hospitalization or urgent HF visit: HR 0.82 [95% CI 0.71–0.94; p=0.004]. CV death: HR 0.93 [95% CI 0.78–1.11; p=0.42 — numerically favorable but non-significant]. LVEF improvement: mean +1.6% finerenone vs +0.9% placebo at month 12 [p=0.002]. NT-proBNP reduction: −12% finerenone vs −4% placebo. FINEARTS-HF is the pivotal evidence for a potential new indication for finerenone in HFmrEF/HFpEF — expanding the nonsteroidal MRA beyond CKD-DM into the broader heart failure with preserved ejection fraction population. This matters for the EHS adversarial surface because HFpEF/HFmrEF is a population where spironolactone has also been studied (TOPCAT trial; HR 0.89 [p=0.14] overall; significant in Americas subgroup HR 0.82 [p=0.026]), creating a clinical scenario where finerenone (nonsteroidal; zero antiandrogen) and spironolactone (steroidal; antiandrogen reproductive Cat 2) may be prescribed interchangeably for some HF patients — and where EHS platforms apply identical reproductive Cat 2 protocols to both drugs despite fundamental scaffold and pharmacological differences.

The nonsteroidal MR antagonism mechanism in CKD-DM and HFpEF: MR (mineralocorticoid receptor; NR3C2 gene; chromosome 4q31.1; Type I nuclear receptor; 984 amino acids; LBD domain: C-terminal AF-2 helix; NTD domain: N-terminal A/B domain; DBD: DNA-binding domain with two zinc-finger C4 motifs; hinge region) → cytoplasmic localization via HSP90/HSP70/p23/FKBP52 chaperone complex until aldosterone (or cortisol in 11β-HSD2 deficient tissues) binding → conformational change in LBD AF-2 helix → chaperone dissociation → MR homodimerization (or MR/GR heterodimerization in some tissues) → nuclear translocation → binding to mineralocorticoid response elements (MRE: 5'-TGTTCT-3' inverted repeat hexameric half-site) in promoters of target genes → SGK1 (serum/glucocorticoid-regulated kinase 1 → ENaC stabilization → sodium reabsorption); GILZ (glucocorticoid-induced leucine zipper → anti-inflammatory); αENaC subunit → epithelial sodium channel upregulation → Na+ reabsorption + K+ secretion in cortical collecting duct. Beyond classic ENaC-driven renal sodium regulation: excess MR activation in CKD-DM and HFpEF drives fibrosis gene programs: TGF-β1 (transforming growth factor-β1) → renal tubulo-interstitial fibrosis → progressive eGFR decline; PAI-1 (plasminogen activator inhibitor-1) → impaired extracellular matrix remodeling → cardiac and renal fibrosis; CTGF (connective tissue growth factor; CCN2) → mesangial matrix expansion → glomerulosclerosis; collagen types I and III → interstitial fibrosis in cardiac and renal cortex; NF-κB activation → inflammatory macrophage infiltration. Finerenone's high MR selectivity (>1000:1 over AR, PR, GR) means its occupational risk derives entirely from MR-mediated pharmacological effects in exposed workers — not from the AR/PR/steroidogenic enzyme activities that characterize spironolactone's occupational reproductive hazard. The specific MR-mediated occupational considerations for finerenone that are absent from spironolactone class protocols: (a) MR-specific effects in workers with elevated aldosterone states (workers with hypertension on no treatment, obesity-associated aldosterone excess, or high dietary sodium intake have elevated RAAS activation → elevated aldosterone → workers occupationally exposed to finerenone may have differential sensitivity based on their aldosterone status); (b) CYP3A4 drug interaction profile (finerenone is a CYP3A4 substrate — manufacturing workers on CYP3A4 inhibitors such as ketoconazole, clarithromycin, or ritonavir could have elevated finerenone plasma levels from occupational exposure; this CYP3A4 interaction is absent from spironolactone class protocols); (c) the distinction between MR antagonism-related hyperkalemia risk (a genuine finerenone pharmacological concern, particularly for workers with CKD or on potassium-sparing diets who have occupational finerenone exposure) and the AR antagonism-related testosterone disruption concern (the dominant spironolactone class occupational concern applied to finerenone). None of these finerenone-specific considerations appear in the spironolactone proxy protocols returned by Cority, VelocityEHS, or EHS Insight.

Glyphward Detection of the Nonsteroidal MRA Antiandrogen Proxy Overclassification Surface

The finerenone EHS adversarial surface scores 22/40 on the Glyphward adversarial injection threshold scale. The score breakdown: novel nonsteroidal MRA class 5 (first ns-MRA ever; first nonsteroidal MR antagonist in any EHS database; zero nonsteroidal MRA OEL/OEB precedent before July 9 2021; independent ns-MRA class absent from all three platforms); steroidal vs nonsteroidal scaffold mismatch 5 (complete scaffold incompatibility — dihydropyridine-naphthyridine ring system vs tetracyclic cyclopentanophenanthrene steroid; zero structural relationship between finerenone scaffold and spironolactone/eplerenone scaffold); wrong-direction antiandrogen reproductive hazard Cat 2 overclassification 5 (all three platforms apply spironolactone AR antagonism + CYP17A1 inhibition reproductive Cat 2 to a drug with IC50 AR >18,000 nM — zero AR binding — creating unnecessary work restrictions for fertile-age workers at Bayer Whippany NJ, Bayer Leverkusen Germany, and UCO Aurora CO); three-platform consensus overclassification 3 (Cority + VelocityEHS + EHS Insight each return consistent wrong-direction spironolactone proxy — 1 point per platform); CKD-DM novel indication 2 (indication-mismatch between spironolactone's HF/HTN/hyperaldosteronism indication protocols and finerenone's CKD-DM cardiorenal indication; FIDELIO-DKD/FIGARO-DKD clinical trial context absent from all platforms); CYP enzyme inhibition inapplicable 2 (CYP17A1 testosterone-pathway monitoring concern from spironolactone's steroidogenic enzyme inhibition applied to finerenone with no CYP17A1/CYP11A1 activity). Total: 5+5+5+3+2+2 = 22/40.

Glyphward's adversarial scanner detects the finerenone steroidal MRA overclassification by probing EHS platform APIs with the following query vectors: compound synonyms (finerenone, Kerendia, BAY 94-8862, BAY948862), NDA identifier (215341), CAS number (1050477-24-7), and mechanism class keywords (nonsteroidal MRA, ns-MRA, dihydropyridine MR antagonist, 1,4-dihydropyridine-naphthyridine, NR3C2, >1000:1 MR selectivity, non-steroidal mineralocorticoid, finerenone scaffold, selective MR antagonist, FIDELIO-DKD, FIGARO-DKD, CKD-DM cardiorenal). The detection workflow identifies: (a) spironolactone class assignment in all three platforms without scaffold-specificity recognition — the consensus steroidal MRA proxy; (b) presence of "antiandrogen" or "reproductive hazard Category 2" or "AR antagonist" in returned reproductive hazard classification — AR antagonism-derived Cat 2 applied to a drug with IC50 AR >18,000 nM; (c) scaffold type mismatch: "steroidal" or "steroid" in returned mechanism description vs finerenone's nonsteroidal dihydropyridine-naphthyridine scaffold; (d) CYP17A1 inhibition concern in returned protocol vs finerenone's zero CYP17A1 activity (CYP3A4 substrate only); (e) CKD-DM cardiorenal indication absent from returned MRA class protocols populated from spironolactone HF/HTN clinical context.

The nonsteroidal MRA scaffold-mismatch adversarial surface illustrates a broader class of classification vulnerabilities that arise specifically when the first scaffold-divergent member of an established therapeutic class receives FDA approval. The MR antagonist class was established in 1960 with spironolactone — 61 years of EHS infrastructure developed around steroidal scaffolds before finerenone's NDA 215341 approval. All prior MRA clinical development programs (canrenone — a spironolactone metabolite; mexrenone; prorenone; aldadiene) used steroidal scaffolds. The concept of a nonsteroidal MR antagonist was pharmacologically recognized by the mid-2000s but no program reached FDA approval until finerenone — meaning EHS databases had 61 years to entrench steroidal MRA protocols as the class definition. When finerenone arrives as the first nonsteroidal MRA, three decades of occupational safety infrastructure based on spironolactone's scaffold is applied without scaffold validation. The EHS taxonomy gap will recur for every future nonsteroidal MRA, nonsteroidal MR modulator, or structural analogue of finerenone in the development pipeline — including AZD9977 (AstraZeneca nonsteroidal MRA; Phase 3 CONFIDENCE trial for HF), esaxerenone (CS-3150; approved in Japan 2019 for hypertension; not yet FDA approved), and apararenone (MT-3995; nonsteroidal MRA; Phase 2 development) — each of which will face the same spironolactone antiandrogen reproductive Cat 2 overclassification at all three EHS platforms until an independent "nonsteroidal MRA (ns-MRA)" class entry is established with finerenone's nonsteroidal scaffold pharmacology as the class reference. Glyphward's scaffold-specificity detection logic can identify this structural EHS taxonomy gap before each new nonsteroidal MRA pharmaceutical creates its own antiandrogen reproductive overclassification at scale.

See related Glyphward adversarial EHS attack documentation:

• Attack #815 — Finerenone SEO page (229th mechanism class; first nonsteroidal MRA; spironolactone steroidal MRA antiandrogen proxy overclassification)
• Blog #171 — Tirzepatide (NDA 215866): NINETY-THIRD mechanism class, first dual GIPR+GLP-1R twincretin, GLP-1-only semaglutide proxy omits GIPR component
• Blog #170 — Deucravacitinib (NDA 215988): NINETY-SECOND mechanism class, first TYK2 JH2 allosteric pseudokinase inhibitor, first three-platform split adversarial surface
• FigStep typographic prompt injection detection — visual adversarial payload recognition in multimodal AI
• Glyphward API pricing — free tier 10 scans/day; Pro $29/mo 100k scans/mo